Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
171,717,172
-
Number of holders
-
133
-
Total 13F shares, excl. options
-
120,556,159
-
Shares change
-
+7,583,828
-
Total reported value, excl. options
-
$2,019,325,029
-
Value change
-
+$125,491,185
-
Put/Call ratio
-
0%
-
Number of buys
-
81
-
Number of sells
-
-31
-
Price
-
$16.75
Significant Holders of Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY) as of Q2 2022
154 filings reported holding RLAY - Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2022.
Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY) has 133 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 120,556,159 shares
of 171,717,172 outstanding shares and own 70.21% of the company stock.
Largest 10 shareholders include SB INVESTMENT ADVISERS (UK) LTD (27,904,963 shares), FMR LLC (13,335,055 shares), VANGUARD GROUP INC (7,098,454 shares), BlackRock Inc. (6,577,178 shares), PRICE T ROWE ASSOCIATES INC /MD/ (5,300,307 shares), JPMORGAN CHASE & CO (4,942,262 shares), STATE STREET CORP (4,778,419 shares), BVF INC/IL (4,384,805 shares), Casdin Capital, LLC (4,068,574 shares), and Bellevue Group AG (4,032,262 shares).
This table shows the top 133 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.